CRIS | Curis, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.06 - 4.45
52 Week Range	3.51 - 17.49
Beta	3.28
Implied Volatility	546.23%
IV Rank	33.78%
Day's Volume	14,849
Average Volume	50,860
Shares Outstanding	8,466,960
Market Cap	34,460,527
Sector	Healthcare
Industry	Biotechnology
IPO Date	2000-08-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.52
Forward P/E Ratio	-3.86
EPS	-7.77
1YR Price Target	17.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	49
Country	USA
Website	CRIS

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

CRIS's peers: ALRN, ARTL, HSTO, TMBR, XFOR, MREO, INZY, TERN, LPTX, DAWN, PDSB, ADAP, PIRS, AFMD, CRVS, APTO

*Chart delayed

Analyzing fundamentals for CRIS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CRIS Fundamentals page.

Watching at CRIS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on CRIS Technicals page.